RxDoctor Payments Data

James Odea, MD

Family Medicine · Cincinnati, OHNPI 1013165174

Payments from drug & device makers

$16,871in general payments, 2019–2025

Across 511 payments — averaging $33.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biomerieux Inc$7K
  • Medtronic$2K
  • AstraZeneca$2K
  • Lilly USA, LLC$942
  • AbbVie$778
  • Novo Nordisk$661
  • plus $4K from 37 others

What the payments were for

  • Consulting fees$4,00524%
  • Travel & lodging$3,72522%
  • Food & beverage$9,12354%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,871 in reported general payments places this provider in the 95th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$90,700
Medicare patients
222
Services billed
1,425

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide92$96,644
EliquisApixaban113$75,423
MounjaroTirzepatide53$68,189
TrulicityDulaglutide41$60,407
JardianceEmpagliflozin56$53,070
Trelegy ElliptaFluticasone/Umeclidin/Vilanter65$52,450
Tresiba Flextouch U-200Insulin Degludec27$39,057
FarxigaDapagliflozin Propanediol30$32,250
XareltoRivaroxaban15$20,258
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog35$18,559
MyrbetriqMirabegron28$16,390
Insulin Lispro Kwikpen U-100Insulin Lispro22$13,839
SymbicortBudesonide/Formoterol Fumarate35$10,586
TradjentaLinagliptin11$10,523
Spiriva HandihalerTiotropium Bromide13$10,360

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$942$128,59594 claims
Novo NordiskOzempic$661$96,64492 claims
PfizerEliquis$440$75,423113 claims
Boehringer IngelheimJardiance, Tradjenta$539$63,59367 claims
GSKTrelegy Ellipta, Anoro Ellipta$639$59,62881 claims
AstraZenecaFarxiga, Symbicort$1,734$42,83665 claims
Johnson & JohnsonXarelto$75$20,25815 claims
AbbVieLinzess, Synthroid$778$9,19455 claims
MerckBelsomra$159$6,35715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →